SCHEMBL63754

SCHEMBL63754

C[N+](C)(C)CCOP(=O)([O-])OC[C@H](O)CO

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 1.00
LMNA P02545 2/20 0.51
AKT1 P31749 2/20 0.51
ESR1 P03372 1/20 0.51
ADORA3 P0DMS8 1/20 0.51
CDC25A P30304 1/20 0.51
AGTR1 P30556 1/20 0.51
ADRA1A P35348 1/20 0.51
KCNH2 Q12809 1/20 0.51
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
PRKD3 O94806 1/20 0.50
PRKCG P05129 1/20 0.50
PRKCB P05771 1/20 0.50
PRKCA P17252 1/20 0.50
PRKCH P24723 1/20 0.50
PRKCI P41743 1/20 0.50
PRKCE Q02156 1/20 0.50
PRKCQ Q04759 1/20 0.50
PRKCZ Q05513 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL245306 1.00 SMN1; SMN2 (1.00) SMN1; SMN2LMNAAKT1ESR1ADORA3
SCHEMBL272506 1.00 SMN1; SMN2 (1.00) SMN1; SMN2LMNAAKT1ESR1ADORA3
Hydrogen Peroxide SCHEMBL15769657 0.98 SMN1; SMN2 (0.97) SMN1; SMN2LMNAAKT1ESR1ADORA3
Methylamine SCHEMBL9699690 0.97 SMN1; SMN2 (0.94) SMN1; SMN2LMNAAKT1ESR1ADORA3
SCHEMBL10586725 0.87 SMN1; SMN2 (0.76) SMN1; SMN2LMNAAKT1ESR1ADORA3
SCHEMBL28965396 0.85 SMN1; SMN2 (0.73) SMN1; SMN2LMNAAKT1ESR1ADORA3
SCHEMBL23199737 0.83 SMN1; SMN2 (0.71) SMN1; SMN2LMNAAKT1ESR1ADORA3
SCHEMBL19821621 0.83 SMN1; SMN2 (0.71) SMN1; SMN2LMNAAKT1ESR1ADORA3
SCHEMBL4989896 0.83 SMN1; SMN2 (0.70) SMN1; SMN2LMNAAKT1ESR1ADORA3
SCHEMBL1853865 0.83 SMN1; SMN2 (0.70) SMN1; SMN2LMNAAKT1ESR1ADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 7630 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260144836-A1 NUTRACEUTICAL FOR ENHANCED COGNITIVE PERFORMANCE Herbanized Wellness, LLC (US) 2026-05-28 US claimed
EP-4746864-A1 C5 KETONE COMPOSITIONS AND RELATED METHODS FOR TREATING METABOLIC DYSFUNCTION Keto Innovations, LLC (US) 2026-05-27 EP claimed
EP-4747627-A1 METHODS AND SYSTEMS FOR PREDICTIVE CLASSIFICATION BY MASS SPECTROMETRY AND TRAINED LARGE SPECTRAL MODELS Matterworks Inc (US) 2026-05-27 EP claimed
CN-122081073-A Excrement fungus cryopreservation liquid and application thereof 2026-05-26 CN claimed
WO-2026106498-A1 PERFUSION FLUID, METHODS OF PRODUCING PERFUSION FLUID, AND ITS USES NanoSanguis S.A. (PL) 2026-05-21 WO claimed
EP-4744486-A1 PERFUSION FLUID, METHODS OF PRODUCING PERFUSION FLUID, AND ITS USES. NanoSanguis S.A. (PL) 2026-05-20 EP claimed
EP-4743094-A1 LIPOSOMAL FORMULATIONS OF CORTICOSTEROIDS AND USES THEREOF Eden Ophthalmic Pte Ltd. (SG) 2026-05-20 EP claimed
EP-4744487-A1 FLUID, METHODS OF PRODUCING FLUID, AND ITS USES NanoSanguis S.A. (PL) 2026-05-20 EP claimed
CN-122056386-A Moisture absorption resistant slow release microcapsule powder and preparation method and application thereof 大连医诺生物股份有限公司 2026-05-19 CN claimed
CN-121673250-B Polyamino cationic lipids containing carbamate structures, compositions comprising same and uses 北京悦康科创医药科技股份有限公司 2026-05-15 CN claimed
EP-0201623-B1 PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF INVOLUTIONAL BRIAN SYNDROMES AND MENTAL DECAY LPB Istituto Farmaceutico s.p.a. (IT) 1990-02-07 EP claimed
WO-1989009600-A1 METHOD AND COMPOSITION FOR TREATING NEUROLOGICAL DISORDERS MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 1989-10-19 WO claimed
US-4792599-A Biocompatible polyesters BIOCOMPATIBLES LTD. (GB) 1988-12-20 US claimed
EP-0275293-A1 POLYESTERS. BIOCOMPATIBLES LTD (GB) 1988-07-27 EP claimed
WO-1988000956-A1 POLYESTERS BIOCOMPATIBLES LIMITED (GB) 1988-02-11 WO claimed
EP-0217258-A2 The use of choline or choline releasing compounds in the production of pharmacological compositions capable of reducing fatigue MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 1987-04-08 EP claimed
EP-0217765-A2 Process for the preparation of L-alpha-glycerylphosphorylcholine, L-alpha-glycerylphosphorylethanolamine from crude and/or deoleated lecithins ISTITUTO CHEMIOTERAPICO ITALIANO FINE CHEMICALS S.p.A. (IT) 1987-04-08 EP claimed
US-4626527-A REDUCING FATIQUE FROM MAJOR EXERCISE MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 1986-12-02 US claimed
US-4624946-A A-GLYCERYLPHOSPHORYLCHOLINE LPB ISTITUTO FARMACEUTICO S.P.A. (IT) 1986-11-25 US claimed
EP-0201623-A1 Pharmaceutical compositions for the treatment of involutional brian syndromes and mental decay LPB Istituto Farmaceutico s.p.a. (IT) 1986-11-20 EP claimed